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Abstract 
Background: Amyloid positron emission tomography (PET) makes it possible to diagnose Alzheimer’s disease (AD) 
in its prodromal phase including mild cognitive impairment (MCI). This study evaluated the cost‑effectiveness of 
including amyloid‑PET for assessing individuals with MCI.
Methods: The target population was 60‑year‑old patients who were diagnosed with MCI. We constructed a Markov 
model for the natural history of AD with the amyloid positivity (AP). Because amyloid‑PET can detect the AP MCI state, 
AD detection can be made faster by reducing the follow‑up interval for a high‑risk group. The health outcomes were 
evaluated in quality‑adjusted life years (QALYs) and the final results of cost‑effectiveness analysis were presented in 
the form of the Incremental Cost‑Effectiveness Ratio (ICER). To handle parameter uncertainties, one‑way sensitivity 
analyses for various variables were performed.
Results: Our model showed that amyloid‑PET increased QALYs by 0.003 in individuals with MCI. The estimated 
additional costs for adopting amyloid‑PET amounted to a total of 1250 USD per patient when compared with the cost 
when amyloid‑PET is not adopted. The ICER was 3,71,545 USD per QALY. According to the sensitivity analyses, treat‑
ment effect of Donepezil and virtual intervention effect in MCI state were the most influential factors.
Conclusions: In our model, using amyloid‑PET at the MCI stage was not cost‑effective. Future advances in manage‑
ment of cognitive impairment would enhance QALYs, and consequently improve cost‑effectiveness.
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Key points
• Using amyloid-PET at the mild cognitive impairment 
(MCI) stage is not cost-effective based on incremen-
tal cost-effectiveness ratio and willingness-to-pay 
thresholds.
• According to sensitivity analyses, future advances in 
management of cognitive impairment could improve 
cost-effectiveness of amyloid-PET in individuals with 
MCI.
Background
According to the worldwide trends of population aging, 
dementia has posed a huge impact on public health in 
almost all countries [1]. Thus, the World Health Organi-
zation and Alzheimer’s Disease International designated 
dementia as a global public health priority [2, 3]. Also in 
South Korea, there were an estimated 6,61,707 persons 
with dementia (about 9.8% of people aged 65 and over) 
[4]. Social costs, including direct and indirect costs, 
were estimated at 18,200 USD per year per patient with 
dementia [4]. In addition, public management costs for 
patients with dementia were estimated at a total 12,600 
million USD [4].
Alzheimer’s disease (AD) is the most common cause 
of dementia [5] and it has a slowly progressing degenera-
tive course [6]. Clinical experts have emphasized early 
diagnosis and treatment of AD [7] as this can enable 
more systematic management planning and education of 
patients/caregivers, and consequently lead to social cost-
savings [7, 8].
Mild cognitive impairment (MCI) has been regarded 
as an intermediate state between normal aging and the 
earliest manifestations of dementia [9]. Individuals with 
MCI can exhibit varying results such as reversion to nor-
mal, sustained MCI, and conversion to dementia [10]. 
The annual rates of conversion from MCI to dementia 
have been known to be around 10–15% [10–12]. And the 
prevalence of MCI is known to be relatively high − 10% 
to 20% of individuals aged 65 or over [13–15]. Therefore, 
many previous researchers have focused on diagnosing 
prodromal AD in individuals with MCI.
Amyloid positron emission tomography (PET) imag-
ing, using radioactive ligands that bind to amyloid 
plaques, makes it possible to diagnose AD in its pro-
dromal phase including MCI [16, 17]. Many research-
ers have discussed the appropriate use of amyloid-PET 
and reported guidelines [18–21]. So far, routine use of 
amyloid-PET in individuals with MCI has not been gen-
erally recommended [18–21] because amyloid-PET only 
detects a brain histological state, not a clinical diagnosis 
and amyloid-lowering therapies have not been developed 
yet [20]. However, since amyloid-PET is helpful for early 
diagnosis and differential diagnosis of AD, the clinical use 
of amyloid-PET has been continuously considered [18–
21]. In addition, many older adults want to know their 
disease status of cognitive disorder earlier [22]. In Korea, 
amyloid-PET is currently excluded from national insur-
ance coverage, but discussions are ongoing on whether 
to include amyloid-PET in national insurance coverage in 
the future [23].
There are some previous studies that claim that amy-
loid-PET is cost-effective in predementia or similar 
states. Hornberger et al. evaluated the cost-effectiveness 
of adopting amyloid-PET in patients with early-stage 
or suspected AD in France and Spain and reported that 
this scanning cost-effectively increases quality-adjusted 
life years (QALYs) [8, 24]. Guo et  al. also showed that 
adopting amyloid-PET in patients with predementia 
and dementia is cost-effective in the United States [25]. 
While these studies show the cost-effectiveness of adopt-
ing amyloid-PET, they did not selectively target patients 
with MCI. MCI patients are in an earlier stage of disease 
progression than those in these previous reports, and the 
results on cost effectiveness of amyloid-PET in MCI can 
be different from those in previous studies.
Therefore, economic analyses of the implementation of 
amyloid-PET in patients with MCI are needed. This study 
evaluated the cost-effectiveness of including amyloid-
PET for assessing individuals with MCI. We believe that 
this may help determine healthcare policy, as well as dic-
tate the indication for amyloid-PET.
Methods
Target population
The target population was 60-year-old patients who were 
diagnosed with MCI. MCI patients have identified cogni-
tive impairment but there is uncertainty about whether 
they have developed AD. Therefore, there is a possibility 
of benefiting from additional interventions such as using 
amyloid-PET.
The age of patients was chosen based on previous stud-
ies and expert opinion that it is generally accepted to be 
earlier than the average age for the onset of AD [26, 27]. 
It was assumed that amyloid plaques accumulation was 
observable at this age.
Comparator
We set the current practice as a comparator. In the cur-
rent practice, amyloid-PET is not recommended for 
general MCI patients [18]. We compared the current 
practice with the implementation of amyloid-PET for all 
diagnosed MCI patients.
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Markov model
We constructed a Markov model for the natural history 
of AD with the amyloid positivity (AP) and amyloid nega-




The progression after AD incidence followed Yu et  al.’s 
and Neumann et  al.’s models [28, 29]. And the progres-
sion before AD incidence (from Clinically Normal to 
mild AD) followed experts’ opinion. It was assumed that 
non-AD dementia could occur but exited from the model 
to focus on the effects on costs and health outcomes 
caused by AD.
The initial condition in all population is MCI. Without 
amyloid-PET, MCI patients could not be classified as AP 
MCI or AN MCI. MCI is clinically reversible; however, 
once AD occurs, it becomes clinically irreversible. Mod-
erate AD can convert to mild AD. AP MCI and AN MCI 
are not interchangeable and all states can lead to death.
Detection of AD
Moderate and severe AD are immediately detected 
because of the severity of their symptoms. However, in 
MCI and mild AD, the patients may not know their exact 
state. Thus, individuals in this category are only diag-
nosed at the time of the follow-up visit. As the follow-up 
interval becomes shorter, patients could know their con-
dition more accurately. For a conservative estimation, 
mild AD was assumed to be detected 3 years after onset 
regardless of a follow-up.
The interval of follow‑up
The interval of follow-up depends on an individual’s 
health state. We assumed that clinically normal persons 
did not get a follow-up, patients with MCI got a follow-
up every year, and AD patients did every three months 
with reference to expert opinion. AP MCI patients were 
assumed to get a follow-up every 3  months after they 
were identified by amyloid-PET. AN MCI patients were 
assumed to get annual follow-up visits.
Treatment of AD
The treatment was assumed to start from the moment 
AD was detected. Therefore, if a patient had not been 
confirmed as having AD by a doctor, he or she would 
not be treated even if they actually had mild AD. At the 
MCI state, any type of treatment was not assumed. AD 
treatment was thought to slow down the progression to a 
more severe cognitive status.
Expected benefit of amyloid‑PET
Because amyloid-PET can detect the AP MCI state, AD 
detection can be made faster by reducing the follow-up 
interval for a high-risk group. Early detection means early 
treatment thereby slowing the AD disease progression.
Parameters
Table 1 shows the model parameters and values applied 
in the analyses. We used the parameters extracted from 
Koreans and then used overseas data if there were no 
appropriate Korean-specific data.
Transition probabilities
Annual transition probabilities between each health state 
were obtained from the Korean longitudinal study on 
cognitive aging and dementia (KLOSCAD) cohort and 
from Neumann et  al. [29, 30]. When AD was detected 
and treatment initiated, the adjusted probabilities were 
applied.
The excess mortality risks of AD
MCI and mild AD were assumed to have the same mor-
tality rates as the rates seen in the clinically normal state, 
which were calculated based on age-specific life tables 
from the Korea National Statistical Office. But moder-
ate and severe AD were assumed to have excess mortal-
ity risks, which were calculated based on Neumann et al.’s 
annual probability [29].
The prevalence of AP MCI
When amyloid-PET was taken in 312 patients diagnosed 
with MCI, 122 (39.1%) patients were classified as AP 
MCI. The results were obtained from MCI patients who 
Fig. 1 Schematic representation of the Markov model
Page 4 of 10Lee et al. Cost Eff Resour Alloc           (2021) 19:50 
Table 1 Model parameters and values applied in the analyses
AD Alzheimer’s disease, AN amyloid negative, AP amyloid positive, HIRA Korean Health Insurance Review & Assessment Service, KNHANES Korea National Health and 
Nutrition Examination Survey, MCI Mild Cognitive Impairment, SR Systematic Review result by authors
a Korean longitudinal study on cognitive aging and dementia. The values in the table are unpublished data. For a description of the KLOSCAD cohort, see Han et al.[30]
b Neumann et al. did not directly present excessive mortality risks [29]. Authors calculated it based on their annual probabilities
c The minimum and maximum value were obtained from Doraiswamy et al. [31], Ong et al. [32], Schreiber et al. [33], and Thurfjell et al.[34]
d The values derived from survey or clinical study performed with this economic evaluation study
e All costs were measured in 2017 and converted as follows: 1,130 KW to 1 USD
f The range of sensitivity analyses for cost items, ± 50% of the base-case value was set to the range
g The minimum and maximum value were obtained from individual studies included in the synthesis
h If the effect is 0.95, it means that the probability of moving from AP MCI state to mild AD state will be 0.95 times
Parameters Point estimates (range for sensitivity analysis) References
Annual transition probabilities
 Clinically normal MCI 0.0341 KLOSCADa
 MCI clinically normal 0.0641 KLOSCAD
 AN MCI mild AD 0.0211 KLOSCAD
 MCI non‑AD dementia 0.0017 KLOSCAD
 Mild AD moderate AD 0.3220 [29]
 Mild AD severe AD 0.0420 [29]
 Moderate AD mild AD 0.0430 [29]
 Moderate AD severe AD 0.3390 [29]
Excess mortality  riskb
 Moderate AD 2.57 [29]
 Severe AD 7.82 [29]
Prevalence of amyloid positivity in MCI 0.3910 (0.3617, 0.5556)c Authord
Relative risk of AD conversion of AP MCI 7.95 (3.53, 15.20)c SR
Diagnostic accuracy of amyloid‑PET
 Sensitivity 0.92 [35]
 Specificity 1 [35]
Quality of life weight
 Clinically normal (age ≥ 65) 0.874 KNHANES
 MCI 0.80 [36]
 Mild AD 0.43 [36]
 Moderate AD 0.21 [36]
 Severe AD 0.17 [36]
Medical cost per year ($)e
 Clinically normal 0 –
 MCI 794 [36]
 Mild AD 2113 [36]
 Moderate AD 1478 [36]
 Severe AD 1819 [36]
Non‑medical cost per year ($)
 Clinically normal 0 –
 MCI 2539 [36]
 Mild AD 10,956 [36]
 Moderate AD 11,796 [36]
 Severe AD 14,273 [36]
Amyloid PET cost ($) 1041 (520, 1561)f Author
Additional follow‑up cost per 1 visit ($) 27 (14, 41)f HIRA + [36]
Treatment effect 0.85 (0.70, 0.93)g SR
Virtual intervention effect for AP  MCIh 1 (0.95, 1) Assumption
Start age 60 (60, 80) –
Discount rate 0.05 –
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underwent amyloid-PET at Korea University Guro Hos-
pital or Seoul National University Bundang Hospital. 
Please e-mail us for more details.
Relative risk of AD conversion from AP MCI
Though the other probabilities in the model were 
obtained from cohort studies, there were no reliable val-
ues for AD incidence rate based on the amyloid positivity 
state. To solve this problem, we conducted a systematic 
literature review to obtain the relative risk of AD con-
version from AP MCI when compared with the rate of 
conversion from AN MCI. The prospective studies that 
observed MCI patients, whose baseline amyloid positiv-
ity state was known over a certain period of time so as 
to observe the incidence of AD, were collected. Finally, 
four studies were selected [31–34] and the relative risk 
was calculated by dividing the rate of AP MCI convert-
ing to AD by the rate of AN MCI converting to AD. As 
a result, we found that AD occurs in AP MCI 7.95 times 
more than in AN MCI. We assumed that the incidence 
of AD in AN MCI was equal to the incidence of AD in 
general MCI.
Diagnostic accuracy of amyloid‑PET
The diagnostic accuracy of amyloid-PET in this study 
indicates its ability to distinguish between AP and AN. 
It is related to whether or not amyloid accumulation in 
the brain is higher than threshold only and is not related 
to the presence of dementia or MCI. We used the results 
obtained from an A16 phase trial, which was the only 
study that used autopsy to confirm amyloid accumulation 
in the brain [35].
Health‑related quality of life
Health-related quality of life was measured using the 
Korean version of the EQ-5D-3L in a survey (Seoul 
National University IRB No. 1707/003–021) linked to 
this study. Participating patients were stratified by sever-
ity and the quality of life weights were also calculated by 
severity [36]. Severity classification followed the Clinical 
Dementia Rating (CDR) [37].
Costs
The costs of this study were derived from the healthcare 
system perspective. Direct medical costs, direct non-
medical costs, time and travel costs for both patients and 
caregivers, care costs including caregivers’ time costs, 
and long-term care costs were included. Productivity 
costs were excluded.
All costs, except direct medical costs, were calculated 
from the survey described above [36]. The responses 
were averaged by CDR severity and adjusted as an annual 
cost. Direct medical costs were calculated by reviewing 
the hospital records and using only the costs associated 
with dementia.
Amyloid-PET testing costs and follow-up costs were 
calculated by multiplying the unit cost by the frequency 
of uses. There is no formal amyloid-PET unit cost 
because amyloid-PET is not reimbursed by National 
Health Insurance (NHI) in Korea. Therefore, the average 
cost of the three hospitals that participated in the study 
was applied. Follow-up cost is the sum of consultation 
fee, travel cost, and time cost. Consultation fee was taken 
from NHI and travel and time cost were calculated from 
the survey.
All costs were measured in 2017 and converted as fol-
lows: 1,130 KW to 1 USD, using the International Mon-
etary Fund’s official exchange rate [38].
Treatment effects
We used synthesis-based estimates when applying treat-
ment effects to AD patients. Donepezil was set as the 
standard of treatment drug and individual literature was 
selected in the Cochrane review published in 2018 [28, 
39]. Only those studies with the Clinician’s Interview-
Based Impression of Change scale (CIBIC-plus) or Clini-
cal Global Impression of Improvement scale (CGIC) 
outcomes were selected to reflect the comprehensive 
improvement of AD symptoms. After extracting the nec-
essary information from the selected studies, the relative 
risk (RR) was calculated using Review Manager 5.3 with 
the fixed effect model chosen based on a small number 
of studies and non-significance of heterogeneity test. The 
synthesized RR was 0.85 (95% CI: 0.80–0.90), implying 
that the probability of an AD patient progressing to an 
advanced state will be lower by 0.85 times when treated 
with Donepezil compared to placebo.
Analysis
The analysis was initiated at age 60 and all subjects were 
analyzed until death. It might be better to set the time 
horizon as a lifetime to include all the costs and health 
outcomes caused by AD. The cycle length of the Markov 
model was set to 3  months to reflect the change in the 
follow-up interval and half-cycle correction was applied. 
We used TreeAge Pro 2019, R2 (TreeAge Software, Inc., 
Williamstown, MA).
The health outcomes of our study were evaluated in 
QALYs, which make it possible to reflect on the major 
disease characteristics of AD, i.e., the declining quality of 
life. Both costs and health outcomes were discounted at 
an annual rate of 5%, as recommended by Korean Health 
Insurance Review & Assessment Service (HIRA) guide-
lines. The final results of cost-effectiveness analysis were 
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presented in the form of the Incremental Cost-Effective-
ness Ratio (ICER).
Sensitivity analyses
To handle parameter uncertainties, one-way sensitivity 
analyses for various variables were performed and pre-
sented in the form of tornadogram.
Base-case analysis assumed no treatment when a 
patient was in the MCI state, but for comparison with 
similar studies [8, 24, 25], we performed a sensitivity 
analysis assuming the existence of virtual interventions 
that could reduce the incidence of AD when in the AP 
MCI state. In such a case, patients identified as AP MCI 
via amyloid-PET would receive additional benefits.
The range of sensitivity analyses used minimum and 
maximum values if there were previous studies. For the 
cost items, ± 50% of the base-case value was set to the 
range. Exceptionally, the annual management cost, which 
is the sum of annual medical cost and non-medical cost, 
used input values of a previous study [25] to compare the 
result directly. The values of the previous study were used 
after adjusting for the inflation rate.
Written informed consent was obtained from all 
the participants and their legal guardian. The neces-
sary ethical permissions were received from the Insti-
tutional Review Board at Korea University Guro 
Hospital (2016GR0003/2016GR0200), Jeju National 
University Hospital (2016–06-017), Seoul National Uni-
versity (1707/003–021), and Seoul National University 
Bundang Hospital (B-1608/360–007).
Results
Table  2 shows the result of base-case analysis. In MCI 
patients, the cost was $60,037 without amyloid-PET 
and $61,287 with amyloid-PET, i.e., a $1,250 increased. 
QALYs were 8.757 and 8.760, respectively, showing an 
increase by 0.003 with amyloid-PET. The ICER was 
$371,545 per QALY.
Figure 2 shows the main results of one-way sensitivity 
analyses. Treatment effect of Donepezil and virtual inter-
vention effect for AP MCI were the most influential fac-
tors. In particular, it seemed cost-effective (ICER $19,461 
per QALY) when the lowest virtual intervention effect 
for AP MCI (0.95) was applied. In all other cases, ICERs 
were larger than $160,000 per QALY.
Discussion
Our results showed that amyloid-PET increased QALYs 
by 0.003 in individuals with MCI. The estimated addi-
tional costs for adopting amyloid-PET in individuals 
with MCI amounted to a total of 1250 USD per patient 
Table 2 Cost‑effectiveness of amyloid‑PET for MCI patients
QALYs quality-adjusted life years, ICER Incremental Cost-Effectiveness Ratio
a This ICER is sensitive to small changes in the QALY difference caused by 
rounding off error
Cost($) ΔCost($) QALYs ΔQALYs ICER
No amyloid‑PET 60,037 8.757
Do amyloid‑PET 61,287 1250 8.760 0.003 3,71,545a
Fig. 2 The tornadogram of one‑way sensitivity analyses
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when compared with the cost when amyloid-PET is 
not adopted. Consequently, the ICER of our model was 
3,71,545 USD per QALY. The threshold for ICER var-
ies in countries. 30,000 EUR (i.e., 35,000 USD), 40,000 
EUR (i.e., 47,000 USD), and 50,000 USD per QALY were 
affordable ICER in Spain, France, and in the United States 
studies on cost-effectiveness of adopting amyloid-PET, 
respectively [8, 24, 25]. In South Korea, though there is 
no official threshold for ICER, willingness-to-pay per 
QALY was estimated at 27,000 USD in 2012 [40]. Even 
after considering inflation, the ICER of our model is con-
siderably higher than the willingness-to-pay per QALY in 
South Korea.
As far as we know, three economic evaluation studies 
about 18F amyloid-PET have been published so far [8, 24, 
25] and our result is the complete opposite of that of pre-
vious studies. We believe that this difference may be due 
to several different settings and assumptions.
First, the assumptions related to disease progres-
sion are different. Previously Spain, France, and United 
States studies assumed that cognitive functioning would 
only deteriorate into dementia from the MCI state if 
not treated [8, 24, 25]. This assumption can increase the 
benefits of amyloid-PET by rating the benefits of early 
detection highly. Unlike these studies, we assumed the 
possibility of reversion to clinically normal from the MCI 
state (0.0641). Some previous studies have reported that 
individuals with MCI could return to cognitively nor-
mal states. Koepsell et  al. showed that 16% of subjects 
diagnosed with MCI reverted back to normal or near-
normal cognition approximately one year later [41]. 
Malek-Ahmadi conducted a meta-analysis and found an 
overall reversion rate of approximately 24% [42]. Our 
assumption reflects these previous studies.
Second, assumptions about treatment are different. 
In our model, it was assumed that treatment could not 
be started immediately, even if brain amyloid accumu-
lation was detected in the elderly with MCI. That is, we 
assumed that treatment for dementia began only when 
the progression to dementia was detected by reflect-
ing the policy and guideline of NHI in South Korea 
[43]. Time of treatment initiation in previous models of 
Spain and France was assumed earlier than that of our 
model [8, 24]. Considering the common assumption that 
dementia medications have some effect in the course 
of cognitive decline, a delayed start of treatment in our 
model may have contributed in part to our high ICER of 
amyloid-PET.
In particular, Guo et al. assumed that virtual treatment 
during the predementia phase would reduce the risk of 
conversion by 50% among those patients with prodromal 
AD [25]. To date, the evidence for interventions to reduce 
the risk of conversion to dementia in predementia is very 
limited [44–47]. As a result of the sensitivity analysis 
using similar assumptions for the comparison with the 
previous studies, we found that the cost-effectiveness of 
amyloid-PET was greatly improved as in Guo et al. [25]. 
This implies that amyloid-PET could be a cost-effec-
tive alternative if interventions that would significantly 
reduce the risk of conversion from MCI to dementia were 
developed, but not cost-effective at the moment. In addi-
tion, previous studies have assumed that the treatments 
for AD have no effect on non-AD dementia. Actually, 
there are pieces of evidence that these are also effective 
in vascular dementia [48] or Parkinson’s disease dementia 
[49]. Thus, the above assumption may have exaggerated 
the benefits of amyloid-PET.
Third, Korea has a relatively low care costs for severe 
AD than other countries. In our study, the annual care 
cost of severe AD was 16,092 USD (medical cost of 1,819 
USD + non-medical cost of 14,273 USD), which was 
approximately 3,000 USD different from mild AD (13,069 
USD) or moderate AD (13,274 USD). Although the sever-
ity classification method and the cost estimation method 
were different, in Guo et  al., the annual care cost was 
about 14,000 USD for mild state, 34,000 USD for mod-
erate state, and 60,000 USD for severe state [25] and in 
the remaining two studies, it was assumed that the care 
time and cost increased rapidly with severity. The time to 
care for severe patient was more than twice the amount 
of time needed to care for mild patient [8, 24]. If the 
cost difference between the severities is large, the ben-
efit from early detection becomes bigger. Our sensitivity 
analysis result was consistent with this. However, when 
we inserted the annual management cost of the previous 
study in the United States, the reduced ICER was still as 
high as 2,60,789 USD.
There are some limitations to our analysis. First, 
because amyloid-PET is a relatively recent technology, 
some data related to it are limited. For example, there 
were no reliable values for the AD incidence rate based 
on the state of amyloid positivity; therefore, we carried 
out a systematic literature review and sensitivity analysis. 
If there was a large-scale cohort study, it would be possi-
ble to obtain a robust value and also obtain values by age.
Second, we did not include reduction in the use of 
other tests caused by including amyloid-PET because 
we believe that such an analysis would be more reflec-
tive of real-life clinical practice. We believe that amyloid-
PET is not yet a replacement of brain structural imaging, 
F-18 fluorodeoxyglucose-PET, and neuropsychological 
testing in real clinical practice. However, some studies 
have reported that amyloid-PET can be associated with 
reduction of other tests. Johnson et  al. included reduc-
tion of other imaging and neuropsychological testing in 
anticipated impact of amyloid-PET [18]. Grundman et al. 
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investigated potential impact of amyloid imaging in 229 
patients with a history of cognitive decline and uncertain 
diagnosis, and reported that amyloid-PET reduced brain 
structural imaging by 24.4% and neuropsychological test-
ing by 32.8% [50]. In this respect, our model may have 
underestimated the benefits of amyloid-PET.
Third, we eliminated non-AD dementia from our 
model. This setting may underestimate the benefit of 
amyloid-PET because amyloid-PET helps to more accu-
rately distinguish types of dementia in patients with 
dementia. However, since our target population were 
MCI patients who had not yet developed dementia, and 
some of the treatments for AD patients are commonly 
used for patients with non-AD dementia [48, 49], the 
setting where amyloid-PET can more accurately diag-
nose the dementia type, leading to an effective treatment, 
poses a risk of overestimating the benefits of amyloid-
PET. Further studies are needed to clarify the economic 
benefits of amyloid-PET populations including non-AD 
dementia patients.
Fourth, we implemented one-way sensitivity analy-
ses to address parameter uncertainties, which failed to 
consider distributional concerns or correlation between 
parameters. A probabilistic sensitivity analysis would be 
preferred in future studies.
Conclusion
This is the first study that has assessed the cost-effective-
ness of adopting amyloid-PET in individuals with MCI 
in South Korea. According to our model, using amy-
loid-PET at the MCI stage is not cost-effective. Future 
advances in management of cognitive impairment could 
enhance QALYs, and consequently improve cost-effec-
tiveness if amyloid-PET is added to manage individuals 
with MCI. We believe that our findings have provided 
more real-life evidence to the present and future health-
care policies with regards to the addition of amyloid-PET 
in the management of MCI.
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